Demographics of Patients Receiving Tecovirimat (TPOXX) for Treatment of Mpox

Mpox Archive Content

You are viewing an archived web page, collected from CDC’s Mpox website. The information on this web page may be out of date.

The data on this page will no longer be updated after 8/7/2023

CDC holds an expanded access Investigational New Drug (EA-IND) protocol for use of tecovirimat (TPOXX) for treatment of mpox. The IND forms are required to be submitted to CDC. The demographics of patients prescribed tecovirimat treatment are based on the patient intake forms CDC has received and abstracted. However, this number underestimates the number of patients who received tecovirimat during the 2022 mpox outbreak as healthcare providers were allowed to start treatment before submitting IND paperwork to CDC.

These data may not reflect the overall population of patients who have been prescribed tecovirimat since CDC did not receive forms for every patient treated with tecovirimat. Some sections of the submitted forms had missing values.

Patient Intake Forms received and abstracted by CDC with valid non-missing data are included in the above figure. An earlier version of the Tecovirimat IND Patient Intake form (v5.1) only collected “Sex”. Among the n=Info from CSV patients with valid non-missing values for “Sex” reported to CDC, Info from CSV were “Male” (Info from CSV%) and Info from CSV (Info from CSV%) were “Female”. These values are not included in the above figure.

Patient Intake Forms received and abstracted by CDC with valid non-missing data are included in the above figure.